

HDClarity

NEWSLETTER

STUDY UPDATE

In the first few months of 2026, the number of successful sampling visits is still averaging over 35 per month, continuing the trend from the previous year. The study has also opened for recruitment in Portugal for the first time, thanks to the addition of Gulbenkian Institute of Molecular Medicine.

The number of critical longitudinal samples also continues to grow and now over 30% of participants have completed at least 2 annual visits and over 100 have completed 3 or more. The record currently stands at 7 longitudinal CSF collections!

HDCLARITY PERIODIC DATASET

The fourth periodic dataset (PDS) was released in March. HDClarity-PDS4 contained data from 999 participants, a sample size almost 50% larger than that in PDS3. It also included 1,443 study visit packages, each including at least one successful CSF collection, which is an increase of over 70% relative to PDS3.

HDCLARITY INVESTIGATOR MEETING

The next HDClarity IM is scheduled to take place on 24th October at the ICE Krakow Congress Centre in Poland, following the EHDN Clinical Research Congress 2026.




This meeting is open to PIs and primary study coordinators from active and future HDClarity sites in Europe and Australasia, after a similar meeting was held for North American sites last year. Please register for the meeting when you receive your invitation or contact HDClarity Central Coordination if you have any questions.

Presentations from the IM will be available to all on the HDClarity.net website.



CHANGES TO SAMPLE PROCESSING

All active sites have now completed the transition to the new serum processing. Serum samples are now divided into smaller 0.5mL tubes and shipped in their own matrix rack as shown below.



Because of the additional space required for the new rack, shipments should now only include four participant samples sets.

Please ensure that your site and lab are using **Lab Manual Version 6.8**.

HDCLARITY SAMPLE USES

HDClarity samples have been provided for many projects and below are some selected publications and presentations:

- A harmonised NfL dataset across Enroll-HD, Track-HD, TrackOn-HD and HDClarity using the IVD grade Elecsys® NfL assay. Eve Tasiudi et al. (HDTC, Palm Springs 2026)
- CSF and Plasma Extracellular Vesicle Proteins as Potential Biomarkers in Huntington's Disease. Chrisovalantis Papadopoulos et al. (HDTC, Palm Springs 2026)
- Exploratory analysis of PENK and PDYN as early markers of HD onset and progression. Julien Peladan et al. (HDTC, Palm Springs 2026)

Please remember....

■ New staff

If you have new staff joining your team, please inform Central Coordination as soon as possible. New staff should not start working on the study until the updated delegation and training logs have been provided and Central Coordination have advised on required training.

■ Serum processing

Please remember that serum processing must start at least 30 minutes (and no more than 40 minutes) after collection to maximise serum yield.

■ Fewer Than 5 Kits Needed?

Please contact HDClarity Central Coordination rather than placing a kit order in the EDC.

MORE INFORMATION

Further information about HDClarity, is available at www.hdclarity.net and www.clinicaltrials.gov.

You can also follow for regular updates on https://bsky.app/profile/did:plc:uo6t3jw5l_cg7haaxbqymymf7n.

The Central Coordination team are always happy to answer any questions (hdclarity-cc@enroll-hd.org).